SURPASS-CVOT Beyond MACE

A 2026 commentary on SURPASS-CVOT argues that the usual three-point major adverse cardiovascular event endpoint may capture only part of tirzepatide's cardiometabolic effects. This is an interpretation of an existing trial, not a new trial or a new analysis of participant records^[1]. Its proposed biological framework is useful for asking better research questions, but it does not prove that any unmeasured mechanism caused the trial's exploratory mortality or kidney signals.

The paper begins with the main SURPASS-CVOT result. Tirzepatide was noninferior to dulaglutide for cardiovascular death, myocardial infarction or stroke, with a hazard ratio of 0.92 and a 95.3% confidence interval from 0.83 to 1.01. Superiority on that primary endpoint was not established. The authors then ask whether a plaque-focused endpoint fully reflects a treatment that changes weight, glycaemia and cardiorenal risk at the same time^[2].

SURPASS-CVOT preserved cardiovascular efficacy

SURPASS-CVOT compared tirzepatide with dulaglutide, an active GLP-1 receptor agonist with established cardiovascular benefit. The commentary stresses that noninferiority against an effective comparator differs from a placebo comparison. It means the prespecified statistical test supported preservation of cardiovascular efficacy within the trial's margin. It does not mean that the two medicines are identical, and it does not establish tirzepatide's superiority for three-point MACE^[2].

The authors also discuss a methodological dispute over the noninferiority margin. SURPASS-CVOT used a margin of 1.05, chosen to preserve at least half of dulaglutide's established effect. A stricter margin derived from another interpretation of REWIND would have changed the inference. This debate does not erase the trial's prespecified result, but it shows why noninferiority depends on assumptions about the comparator and the constancy of its effect across different trial populations^[2].

The commentary shifts attention beyond three-point MACE

Three-point MACE was built around cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. The commentary describes it as well suited to atherothrombotic events. The authors argue that metabolic disease also involves kidney decline, heart failure, microvascular dysfunction and inflammatory stress linked to visceral or ectopic fat. Those processes matter clinically, but SURPASS-CVOT did not validate the paper's proposed framework as a new endpoint model^[2].

The paper highlights exploratory trial findings that pointed in a similar direction. All-cause mortality favored tirzepatide, with a hazard ratio of 0.84. A four-component MACE endpoint that added coronary revascularization had a hazard ratio of 0.88. A prespecified exploratory kidney analysis reported a hazard ratio of 0.77 for its primary composite renal outcome. Because superiority for the primary three-point MACE endpoint was not established, hierarchical testing stopped. These later results therefore remain exploratory rather than confirmatory^[2].

That statistical boundary is central. Several favorable secondary estimates cannot be combined into proof of one biological pathway. They can justify further trials designed around kidney progression, heart failure or recurrent events. They cannot show that an individual outcome occurred because of GIP receptor activity or because a standard MACE endpoint missed a hidden benefit.

The biological explanation remains a hypothesis

The authors describe tirzepatide as a single molecule that activates GIP and GLP-1 receptors, then propose a wider concept of systemic cardiometabolic vulnerability. Their account links ectopic fat, inflammation, impaired microvascular function and cardiorenal stress. Yet the commentary did not measure those proposed pathways inside SURPASS-CVOT. It draws on related preclinical and observational work, so the mechanism should be read as a plausible model rather than a demonstrated chain of cause and effect^[2].

A mediation analysis from earlier SURPASS trials estimated that changes in body weight and HbA1c accounted for 45.9% of the improvement in albuminuria. The commentary uses the remaining proportion to motivate mechanisms beyond those two measured intermediates. That calculation does not identify the missing mechanism, however. Mediation estimates rely on model assumptions and cannot by themselves prove that inflammation, ectopic fat or receptor-specific activity produced the rest of the association^[2].

Readers who need medicine-specific evidence can use our tirzepatide research overview. Regulatory status is a separate question from endpoint interpretation, and our United States tirzepatide regulation page covers that boundary. Neither route turns this commentary into treatment guidance.

What future cardiovascular trials could test

The paper proposes complementary endpoint structures rather than abandoning MACE. Possibilities include hierarchical composites that incorporate mortality, heart failure events or kidney progression. Recurrent-event analyses could count more than the first event, while multistate models could describe movement between disease states. Enrolling populations whose risk is dominated by metabolic and cardiorenal disease might also make a treatment's intended biology easier to test^[2].

These are design proposals. A broader composite can capture more dimensions, but it can also become harder to interpret when frequent, less severe components drive the result. Each component still needs transparent reporting. A trial should prespecify its hierarchy and multiplicity plan so exploratory signals are not presented as confirmed effects after the primary test fails.

What we do not yet know

We do not know whether an endpoint architecture built around systemic cardiometabolic vulnerability would produce a different confirmatory conclusion for tirzepatide. The commentary offers no prospective validation of its framework. It also cannot separate the effects of GIP receptor activation from weight loss, glucose reduction or other downstream changes in the existing trial.

Future trials would need to define the proposed biological domain before enrollment, measure relevant pathways and test outcomes with adequate statistical control. Until then, SURPASS-CVOT supports noninferiority to dulaglutide for three-point MACE. The wider mortality and kidney pattern remains important research context, not proof that MACE has become obsolete or that tirzepatide provides superior cardiovascular protection.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.